Evidence map›Paper›PMID 18216121›Full record

ArticleJournal of virology2008

Immunomodulatory properties of a viral homolog of human interleukin-10 expressed by human cytomegalovirus during the latent phase of infection.

C Jenkins, W Garcia, M J Godwin, J V Spencer, J Lewis Stern, A Abendroth, B Slobedman

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 112 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. The immunomodulatory role of human cytomegalovirus in cancer in the era of checkpoint immunotherapy.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025
    Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Cytomegalovirus viremia as a risk factor for mortality in HIV-associated cryptococcal and tuberculous meningitis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Control of Cytokines in Latent Cytomegalovirus Infection.Pathogens (Basel, Switzerland) · 2020
    Review
  19. Review
  20. Article

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

C JenkinsCentre for Virus Research, Westmead Millennium Institute, P.O. Box 412, Westmead, NSW 2145, Australia. barry_slobedman@wmi.usyd.edu.au.
W Garcia
M J Godwin
J V Spencer
J Lewis Stern
A Abendroth
B Slobedman
University of Sydney · AUUniversity of San Francisco · US

Funding

Modulation of Monocyte Function by Cytomegalovirus IL-10R03AI063529 · NIAID · UNIVERSITY OF SAN FRANCISCO · PI SPENCER, JULIET VESCIO · 2005 to 2006
$131k
NIAID NIH HHS R03 AI063529
6 · The paper itself

Abstract

Human cytomegalovirus (HCMV) establishes a latent infection in hematopoietic cells, from which it can reactivate to cause significant disease in immunocompromised individuals. HCMV expresses a functional homolog of the immunosuppressive cytokine interleukin-10 (termed cmvIL-10), and alternate splicing of the cmvIL-10 transcript results in expression of a latency-associated cmvIL-10 transcript (LAcmvIL-10). To determine whether LAcmvIL-10 encodes immunosuppressive functions, recombinant LAcmvIL-10 protein was generated, and its impact on major histocompatibility complex class II (MHC-II) expression was examined on granulocyte macrophage progenitor cells (GM-Ps) and monocytes. LAcmvIL-10 (and cmvIL-10) downregulated MHC-II on the surfaces of both cell types. This downregulation was associated with a decrease in total MHC-II protein and transcription of components of the MHC-II biosynthesis pathway. Unlike cmvIL-10, LAcmvIL-10 did not trigger phosphorylation of Stat3, and its ability to downregulate MHC-II was not blocked by neutralizing antibodies to the human IL-10 receptor, suggesting that LAcmvIL-10 either does not engage the cellular IL-10 receptor or utilizes it in a different manner from cmvIL-10. The impact of LAcmvIL-10 on dendritic cell (DC) maturation was also assessed. In contrast to cmvIL-10, LAcmvIL-10 did not inhibit the expression of costimulatory molecules CD40, CD80, and CD86 and the maturation marker CD83 on DCs, nor did it inhibit proinflammatory cytokines (IL-1alpha, IL-1beta, IL-6 and tumor necrosis factor alpha). Thus, LAcmvIL-10 retains some, but not all, of the immunosuppressive functions of cmvIL-10. As GM-Ps and monocytes support latent infection, expression of LAcmvIL-10 may enable HCMV to avoid immune recognition and clearance during latency.

Indexed as

Immune ToleranceVirus LatencyAntigens, CDAntigens, SurfaceCytokinesCytomegalovirusCytomegalovirus InfectionsDendritic CellsDown-RegulationFlow CytometryHistocompatibility Antigens Class IIHumansMonocytesMyeloid Progenitor CellsPhosphorylationReceptors, Interleukin-10Antigens, CDAntigens, SurfaceCMV IL-10 protein, CytomegalovirusCytokinesHistocompatibility Antigens Class IIReceptors, Interleukin-10STAT3 protein, humanSTAT3 Transcription FactorViral Proteins

Identifiers

PMID18216121
PMCPMC2268454
OpenAlexW2147428033

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.